Marclébio Dourado

In the ACHIEVE-1 phase 3 trial, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes. Full trial results: nej.md/4ngEZ36 #ADASciSessions

Lupus nephritis-related chronic kidney disease - Nature Reviews Rheumatology Each episode of lupus nephritis causes irreversible kidney injury, initiating and, subsequently, exacerbating chronic kidney disease. This Review discusses how interdisciplinary care that considers al...

As today is World Lupus Day, we are highlighting some of our lupus content🦋:

Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy bit.ly/3zkO1rK

Lupus nephritis-related chronic kidney disease bit.ly/40fvZCf

An interesting news story about CKD

'25 years ago, CKD was the 19th leading cause of death. Today it sits at 9th

"By 2050, it is projected to be the fifth leading cause of death. That is an unacceptable trajectory for a disease that is largely preventable."

amp.9news.com.au/article/5f36...

Daily monitoring of sCys in patients at risk of AKI would facilitate timely detection and potentially improve clinical outcomes. Future research should focus on validating sCys diagnostic criteria and integrating it with other biomarkers to enhance AKI management. bit.ly/CJASN0654
#ASNCJASN

Cover of the March issue of Nature Reviews Nephrology

In our March issue: Reviews on integrins, endothelin-receptor antagonists, tubule–glomerulus crosstalk and collagens, plus Comments for #WorldKidneyDay on CKD screening, awareness, risk factors and AI-assisted detection go.nature.com/419A0GY

Estimating global article processing charges paid to six publishers for open access between 2019 and 2023 This study presents estimates of the global expenditure on article processing charges (APCs) paid to six publishers for open access between 2019 and 2023. APCs are fees charged for publishing in some ...

Fascinating read on the ever frustrating topic of publication fees: this paper estimates that between 2019 and 2023 researchers and institutions paid a whopping USD $8.968 billion for their findings to be freely accessible and that costs tripled during that time 💰

arxiv.org/abs/2407.16551

Editorial by Jung-Im Shin, Antoine Créon, and Juan-Jesus Carrero:

Metformin in People With Diabetes and Advanced CKD: Should We Dare?

https://bit.ly/3P4BPzy (FREE)

SGLT2 inhibitors and kidney/bladder cancer?

"Investigating risk of cancer with SGLT-2 Inhibitors: A Case/Non-Case Study in the WHOGlobal Pharmacovigilance Database"

www.sciencedirect.com/science/arti...

🌟 KDIGO is now on Bluesky! 🌟

We’re excited to connect with the nephrology community on this platform and share the latest from KDIGO, including guidelines, reports, and educational resources.

We’d like to introduce KDIGO, what we do, and how to connect with us. 🧵👇

🔗 kdigo.org

#NephSky

Apixaban vs The World: Which Anticoagulant is Best for A-fib in CKD? AJKDBlog Interviews Editor Timothy Yau (@Maximal_Change) caught up with Kueiyu Joshua Lin to discuss his study recently published in AJKD comparing the safety and effectiveness of warfarin or rivar…

Counting down the Top Ten #AJKDBlog posts of 2024:

Interviews Editor @maximalchange.bsky.social interviews Kueiyu Joshua Lin on his study recently published in AJKD:

3️⃣ Apixaban vs The World: Which Anticoagulant is Best for A-fib in CKD?

https://bit.ly/3wELWWb (FREE)

Kidney Biopsy Proven Diabetic and Non-Diabetic Kidney Disease and Outcomes in Dialysis Patients With Type 2 Diabetes: The REIN Registry

https://buff.ly/41M7ihk

Advancing Genetic Testing in Kidney Diseases: Report From a NKF Working Group

https://bit.ly/3ZA99V5 (FREE)

Hello, #MedSky community! We’re excited to begin our Bluesky journey.

Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

Renal Physiology for the Clinician Series
#Nephpearls

👉 journals.lww.com/cjasn/pages/...

Hi everyone. Here to follow #NephSky ✔️